Sanofi (NASDAQ:SNY) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Sanofi (NASDAQ:SNYGet Free Report) have earned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $60.00.

A number of equities research analysts recently commented on SNY shares. StockNews.com started coverage on shares of Sanofi in a research report on Thursday, October 5th. They issued a “buy” rating for the company. Stifel Nicolaus downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Berenberg Bank upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 5th.

Get Our Latest Stock Analysis on SNY

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $47.02 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.21 and a debt-to-equity ratio of 0.20. The company has a market cap of $118.94 billion, a P/E ratio of 14.74, a PEG ratio of 2.00 and a beta of 0.60. Sanofi has a 52 week low of $42.63 and a 52 week high of $57.82. The company has a 50-day moving average price of $51.21 and a 200 day moving average price of $52.28.

Sanofi (NASDAQ:SNYGet Free Report) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.02. The firm had revenue of $13.02 billion during the quarter, compared to the consensus estimate of $13.61 billion. Sanofi had a net margin of 17.34% and a return on equity of 27.55%. Research analysts predict that Sanofi will post 4.37 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SNY. Fairfield Bush & CO. purchased a new position in shares of Sanofi during the 1st quarter worth approximately $26,000. Bank of New York Mellon Corp increased its stake in shares of Sanofi by 31.3% during the 1st quarter. Bank of New York Mellon Corp now owns 440,646 shares of the company’s stock worth $22,623,000 after purchasing an additional 105,046 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in shares of Sanofi by 12.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 24,613 shares of the company’s stock worth $1,264,000 after purchasing an additional 2,805 shares in the last quarter. Yousif Capital Management LLC increased its stake in shares of Sanofi by 45.2% during the 1st quarter. Yousif Capital Management LLC now owns 42,041 shares of the company’s stock worth $2,158,000 after purchasing an additional 13,095 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Sanofi by 0.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 300,009 shares of the company’s stock worth $15,402,000 after purchasing an additional 1,391 shares in the last quarter. 10.06% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

(Get Free Report

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Read More

Analyst Recommendations for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.